SyntheMed, Inc.
SyntheMed helps keep surgery patients from getting scars. The company develops polymers aimed at preventing or reducing post-operative adhesions (scar tissue) for a variety of surgical procedures. In 2006 its REPEL-CV product received marketing approval from European Union regulatory authorities for prevention of scar tissue in open heart surgeries; the company launched the product in Europe and some Asian markets through a network of independent distributors. It has received approval from the FDA for use in pediatric cardiac surgery patients in the US. SyntheMed is developing similar products for use in gynecological, abdominal, orthopedic, spinal, and general surgeries.
Contact Details
Executives
Chairman
Richard L. Franklin
President, CEO, CFO, and Director
Robert P. Hickey